McKesson agrees to acquire Precision Medicine for $2.25B
McKesson shares jumped after the company announced a $2.25B deal for Precision Medicine. The move puts the market’s focus on whether the acquisition can add growth without worsening McKesson’s already-thin profitability.
STOCK PHOTO · MARKUS WINKLERThe story
The reported transaction values McKesson’s Precision Medicine deal at $2.25B, with the stock rising after the announcement. No further transaction terms, including the expected closing date, financing structure, or projected financial contribution, were provided in the supplied material.
McKesson generated $403.4B of revenue in the fiscal year ended 2026-03-31, up 12.4% year over year, but its reported margins were 3.6% gross and 1.2% net, alongside diluted EPS of $38.38. Those figures frame the acquisition as a potentially meaningful strategic addition to a very large, low-margin distribution business.
The next evidence points are management’s rationale for the purchase, any guidance impact, funding details, and Precision Medicine’s growth and profitability profile. The deal’s closing timetable and the company’s next earnings update are also important open items.
Our read · Tue, Aug 25
The $2.25B Precision Medicine deal is a mixed read for MCK: it adds a growth vector to a $403.4B-revenue business, but the thin 1.2% net margin leaves execution and funding terms central to the setup.
Why. The immediate upside from the acquisition announcement is not enough to establish a directional trade because the supplied report gives no terms on funding, earnings contribution, or closing timing. McKesson’s 12.4% revenue growth is constructive, but its 1.2% net margin makes the quality of any incremental growth and the transaction’s effect on profitability the deciding evidence.
Both cases
What could change this view: The setup fails if subsequent deal disclosures show limited growth or profitability contribution, or if funding and integration costs weigh on McKesson’s thin net margin.
Who reported it · 2
Keep reading
More on MCK
Hackers claim millions of patient records stolen during data breach at healthcare giant McKessonLatest on the Wire
German producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinue on the Wire →Latest on the Wire
PIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandBiohaven reports confirmed BHV-1530 responses in two FGFR3 cancersTrump, Xi and Putin pledge more refined fuel after first trilateral summitContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by Investing.com as McKesson stock jumps on $2.25B Precision Medicine deal
, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →